Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.63 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836053 | 0.92 | CACNA1B (0.72) | CACNA1BCPB2CTSLCTSS | |
| SCHEMBL4845573 | 0.91 | CACNA1B (0.60) | CACNA1BCPB2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4844358 | 0.88 | CACNA1B (0.67) | CACNA1BCPB2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5357922 | 0.88 | CACNA1B (0.73) | CACNA1BCPB2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4842655 | 0.87 | CACNA1B (0.71) | CACNA1BCPB2CTSLCTSS | |
| SCHEMBL4836033 | 0.87 | CACNA1B (0.72) | CACNA1BCPB2CTSLCTSS | |
| Hydrochloric Acid SCHEMBL4844885 | 0.86 | CACNA1B (0.71) | CACNA1BCPB2CTSLCTSS | |
| SCHEMBL4844475 | 0.85 | CACNA1B (0.66) | CACNA1BCPB2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4847501 | 0.85 | CACNA1B (0.66) | CACNA1BCPB2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4846343 | 0.85 | CACNA1B (0.66) | CACNA1BCPB2ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | claimed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1097929-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | claimed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-6903119-B1 | Amino acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1097929-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1B, CACNA1A | CACNA1B 2/4885CPB2 3070/4885ALDH1A1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.